Abemaciclib, inhibitor aromatase, Eli Lilly na Company, terapi éndokrin, Tamoxifen, Verzenio
Abemaciclib kalayan terapi endokrin disatujuan ku FDA dina kanker payudara HER 2 positif
Maret 2023: Abemaciclib (Verzenio, Eli Lilly and Company) sareng terapi éndokrin (tamoxifen atanapi inhibitor aromatase) parantos disatujuan ku Administrasi Pangan sareng Narkoba (FDA) pikeun pengobatan adjuvant pasien dewasa kalayan ..
Uji coba terapi CAR T Cell, Glioblastoma, percobaan glioblastoma, glioma
Studi Kasalametan sareng Efficacy Terapi Sél Anti-B7-H3 CAR-T pikeun Glioblastoma Kumbuh
Maret 2023: Jenis Studi : Intervensi (Uji Coba Klinis)Estimasi Pendaptaran : 30 pamilonAlokasi: N/Model Intervensi: Penugasan BerurutanIntervensi Katerangan Modél: desain "3+3" digunakeun pikeun nangtukeun Maksimum..
Masarakat Hematologi Amérika, Carteyva, Cina, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Nampilkeun Data Klinis Panganyarna dina Carteyva® dina Follicular Lymphoma sareng Mantle Cell Lymphoma dina Rapat Taunan ASH ka-64
SHANGHAI, CHINA, 12 Désémber 2022 Perusahaan biotéhnologi mandiri sareng kreatif anu disebut JW Therapeutics (HKEX: 2126) museurkeun kana ngembangkeun, manufaktur, sareng ngajual produk imunoterapi sél. Di 64th American Society..
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly disatujuan ku FDA pikeun kanker endometrium dMMR
Pebruari 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) dipasihan persetujuan FDA pikeun ngubaran pasien dewasa anu kakurangan perbaikan mismatch (dMMR) kambuh atanapi kanker endometrium maju anu parantos ningkat salami atanapi saatos ..
Daiichi Sankyo, TAKDIR-Dudung04, Enhertu, fam-trastuzumab deruktecan-nxki
Fam-trastuzumab deruxtecan-nxki disatujuan ku FDA pikeun kanker payudara HER2-low
Agustus 2022: Pikeun penderita sawawa sareng kanker payudara unresectable atanapi métastatik HER2-low (IHC 1+ atanapi IHC 2+/ISH) anu parantos nampi kémoterapi sateuacana dina setting métastatik atanapi ngalaman kambuh deui salami atanapi dina genep.
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA
Olaparib disatujuan pikeun pengobatan adjuvant kanker payudara awal anu résiko luhur
Maret 2022: Administrasi Pangan sareng Narkoba parantos nyatujuan olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) pikeun pengobatan adjuvant pasien dewasa anu ngarusak atanapi disangka ngarusak germline BRCA-mutated (gBRCAm) h..
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Ubar disatujuan pikeun pengobatan kanker ati
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
FDA, KRAS G12C, Lumakras, Nsclc, sotorasib
FDA parantos nyatujuan terapi anu ditargetkeun munggaran pikeun mutasi kanker paru-paru anu saacanna dianggap tahan ubar
20 Agustus 2021: Nembe dina bulan Méi, 2021 Lumakras (sotorasib) disahkeun ku Administrasi Pangan sareng Narkoba AS salaku pangobatan anu pangpayunna pikeun penderita sawawa anu kanker paru-paru sél alit anu parantos ngalaman sahenteuna hiji sistem sateuacanna ..
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, RESÉS, USFDA
Pembrolizumab disatujuan ku FDA pikeun pengobatan adjuvan melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
Ablynx, ADAMTS13, CABLIVI, caplacizumab-yhdp, FDA, Terapi imunosupresip, USFDA
Caplacizumab-yhdp disatujuan ku FDA
Dina Pébruari 6, 2019, ditéang sareng bursa plasma sareng perlakuan imunosupresip, Administrasi Pangan sareng Narkoba nyatujuan caplacizumab-yhdp (CABLIVI, Ablynx NV) pikeun penderita sawawa kalayan thrombotictopeni thrombotic ..